These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3007366)

  • 1. [Clinical pharmacology of ofloxacin: a new chemotherapeutic agent belonging to the gyrase inhibitor group].
    Verho M; Dagrosa EE; Malerczyk V
    Infection; 1986; 14 Suppl 1():S47-53. PubMed ID: 3007366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple-dose pharmacokinetics of ofloxacin, a new broad-spectrum antimicrobial agent.
    Dagrosa EE; Verho M; Malerczyk V; de Looze S; Hajdú P; Toyodera K
    Clin Ther; 1986; 8(6):632-45. PubMed ID: 3466701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International experiences with ofloxacin, a new quinolone.
    Mitsuhashi S
    Infection; 1986; 14 Suppl 4():S223-5. PubMed ID: 3028965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose linearity and other pharmacokinetics of ofloxacin: a new, broad-spectrum antimicrobial agent.
    Verho M; Malerczyk V; Dagrosa E; Korn A
    Pharmatherapeutica; 1985; 4(6):376-82. PubMed ID: 3866256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose linearity testing of intravenous ofloxacin, a novel gyrase inhibitor.
    Verho M; Korn A; Badian M; Malerczyk V; Waldhäusl W
    Chemotherapy; 1988; 34(3):170-7. PubMed ID: 3166420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ofloxacin: its pharmacology, pharmacokinetics, and potential for clinical application.
    Drew RH; Gallis HA
    Pharmacotherapy; 1988; 8(1):35-46. PubMed ID: 3287354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ofloxacin].
    Katsu M; Saito A
    Jpn J Antibiot; 1986 Apr; 39(4):889-904. PubMed ID: 3531566
    [No Abstract]   [Full Text] [Related]  

  • 8. Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Monk JP; Campoli-Richards DM
    Drugs; 1987 Apr; 33(4):346-91. PubMed ID: 3297617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ofloxacin: bactericidal effect in an in vitro pharmacokinetic model.
    Xerri L; Broggio R; Guerra L
    Chemioterapia; 1986 Apr; 5(2):83-7. PubMed ID: 3085961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics and tissue penetration of ofloxacin.
    Lockley MR; Wise R; Dent J
    J Antimicrob Chemother; 1984 Dec; 14(6):647-52. PubMed ID: 6596301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ofloxacin: in vitro and in vivo activity.
    Guerra L; Caro B; Erani E; Xerri L
    Chemioterapia; 1987 Feb; 6(1):23-31. PubMed ID: 3470154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial activity of ofloxacin and other 4-quinolone derivatives: in-vitro and in-vivo comparison.
    Chantot JF; Bryskier A
    J Antimicrob Chemother; 1985 Oct; 16(4):475-84. PubMed ID: 3864775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of ofloxacin after parenteral and oral administration.
    Lode H; Höffken G; Olschewski P; Sievers B; Kirch A; Borner K; Koeppe P
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1338-42. PubMed ID: 3479046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Gyrase inhibitor].
    Forth W
    Klin Wochenschr; 1985 Oct; 63(19):1036-9. PubMed ID: 2999503
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients.
    Naber KG; Adam D; Kees F
    Drugs; 1987; 34 Suppl 1():44-50. PubMed ID: 3481328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro activity, serum, urine and prostatic adenoma concentrations of ofloxacin in urologic patients with complicated urinary tract infections].
    Naber KG; Adam D; Wittenberger R; Bartosik-Wich B
    Infection; 1986; 14 Suppl 1():S60-4. PubMed ID: 2420725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biotransformation of selected gyrase inhibitors].
    Borner K; Lode H
    Infection; 1986; 14 Suppl 1():S54-9. PubMed ID: 3007367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative pharmacokinetic parameters of new systemic fluoroquinolones.
    Neuman M
    Int J Clin Pharmacol Res; 1987; 7(3):173-9. PubMed ID: 3298083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin).
    Mitscher LA; Sharma PN; Chu DT; Shen LL; Pernet AG
    J Med Chem; 1987 Dec; 30(12):2283-6. PubMed ID: 2824776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical pharmacokinetics of levofloxacin.
    Fish DN; Chow AT
    Clin Pharmacokinet; 1997 Feb; 32(2):101-19. PubMed ID: 9068926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.